Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01593228 · ClinicalTrials.gov registry record · Phase 3
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 37
- Enrollment target
NCT01593228 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 37 participants.
The verdict
NCT01593228, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of iniparib administered as monotherapy or in combination regimens in patients previously treated with iniparib in a clinical study and who have derived clinical benefit after completion of the parental study's objectives.
Interventions
- DRUG Carboplatin
- DRUG Gemcitabine
- DRUG Irinotecan
- DRUG Iniparib (SAR240550/BSI-201)
- DRUG Doxorubicin HCL liposome injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2012-05 |
| Est. Completion | 2016-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01593228
The ClinicalTrials.gov registry entry for NCT01593228 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT01593228 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01593228 about?
NCT01593228 is a clinical study titled "Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial". The purpose of this study is to assess the safety and tolerability of iniparib administered as monotherapy or in combination regimens in patients previously treated with iniparib in a clinical study and who have derived clinical benefit after completion of the parental study's objectives.
What is the current status of trial NCT01593228?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 37 participants. The study started on 2012-05. Estimated completion is 2016-09.
What interventions are being tested in trial NCT01593228?
The interventions under investigation include: Carboplatin (DRUG), Gemcitabine (DRUG), Irinotecan (DRUG), Iniparib (SAR240550/BSI-201) (DRUG), Doxorubicin HCL liposome injection (DRUG).
Who is sponsoring clinical trial NCT01593228?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.